Drug intelligence / Profile preview

NV-001

Development stage: Phase 1
Lead developer: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Modality: Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous, Intravenous

Overview

NV-001 appears to exist as two distinct therapeutic candidates with the same code name: 1. A therapeutic cancer vaccine developed by Cancer Hospital Chinese Academy of Medical Sciences. It is a hybrid-membrane-based tumor vaccine generated by hybridization of tumor cell membrane and adjuvant membrane designed to stimulate immune reactions against cancer. 2. A mesenchymal stem cell therapy initially developed by Novellus LLC and also being developed by Citius Pharmaceuticals for respiratory conditions including COVID-19 and respiratory distress syndrome.

Beyond the preview

Go deeper on NV-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NV-001.

Explore the full profile